Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Ardelyx, Inc. (Nasdaq: ARDX) reported its fourth-quarter and full-year 2021 financial results, highlighting a revenue increase of 33% to $10.1 million. The company is set to launch IBSRELA for IBS-C treatment in April 2022. Despite a net loss of $158.2 million, Ardelyx is optimistic about achieving breakeven with IBSRELA and potential profitability. The company also announced a new term loan agreement of $27.5 million, extending its cash position to support this launch. Total cash reserves were $116.7 million as of December 31, 2021.
- Revenue increased by 33% to $10.1 million in 2021.
- Plans to launch IBSRELA in April 2022, marking a significant product debut.
- New term loan of $27.5 million supports IBSRELA launch, providing extended cash runway.
- Net loss for 2021 rose to $158.2 million from $94.3 million in 2020.
- Research and development expenses increased by 40% to $91.1 million.
- General and administrative expenses surged 118% to $72.3 million.
WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business events and financial results for the fourth quarter and full year ended December 31, 2021.
"With a tumultuous 2021 behind us, Ardelyx is positioned to be a biopharma standout in 2022 with our evolution to a commercial stage company with our April launch of IBSRELA for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults," said Mike Raab, president and chief executive officer of Ardelyx. "This year we become a revenue-generating company commercializing a novel mechanism treatment we developed, with a clear line of sight to breakeven and, ultimately, profitability for the product, which we believe will create significant shareholder value. I want to recognize the entire Ardelyx team whose dedication over the years has brought us to this critical inflection point. Every single team member has an unyielding commitment to patients that fuels our mission to bring to market a diverse pipeline of drug candidates and provide the company optionality. We are very excited to see our first drug enter the market and improve the lives of patients with IBS-C."
Recent Business Events
- The company plans to launch IBSRELA (tenapanor), the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in April of 2022.
- The company's collaboration partner, Kyowa Kirin Co. Ltd., (KKC) announced positive Phase 3 results of tenapanor for hyperphosphatemia in patients on hemodialysis in Japan and plans to file for approval in the second half of 2022 with potential regulatory approval in the second half of 2023.
- On February 4, 2022, the company received an Appeal Denied Letter ("ADL") from the Office of Cardiology, Hematology, Endocrinology and Nephrology ("OCHEN") of the U.S. Food and Drug Administration (the "FDA") in response to its Formal Dispute Resolution Request ("FDRR") submitted in early December 2021. In February 2022, the company submitted an appeal of the ADL to the Office of New Drugs ("OND"), Center for Drug Evaluation and Research. If accepted for consideration, the company expects a decision on the appeal to the OND in April 2022.
- On February 24, 2022, the company announced it is paying off the remainder of
$25.0 million in principal plus interest outstanding under the Loan and Security agreement entered into among the company, Solar Capital Ltd. and Western Alliance Bank in May 2018, and has entered into a new term loan with SLR Investment Corp. for$27.5 million , which provides for two years of interest only payments, and an option for an additional$22.5 million in term loan debt if the company receives FDA approval for XPHOZAH® (tenapanor) by December 31, 2022, and meets certain net revenue criteria and other conditions. This further extends the company's cash position in support of the IBSRELA launch.
Full Year 2021 Financial Results
- Cash Position: As of December 31, 2021, we had total cash, cash equivalents and short-term investments of
$116.7 million , as compared to total cash, cash equivalents and investments of$188.6 million as of December 31, 2020. - Revenue: We generated
$10.1 million in revenue for the year ended December 31, 2021, an increase of$2.5 million , or 33 percent, compared to$7.6 million for the year ended December 31, 2020. The increase in our revenue was primarily the result of a$5.0 million development milestone which we earned in 2021 upon the initiation by KKC of Phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. - R&D Expenses: Research and development expenses were
$91.1 million for the year ended December 31, 2021, an increase of$26.1 million , or 40 percent, compared to$65.1 million for the year ended December 31, 2020. The increase in our R&D expenses is primarily the result of tenapanor manufacturing costs as well as clinical study costs from the advancement of our OPTIMIZE study which were partially offset by lower costs for the PHREEDOM Phase 3 clinical study, which concluded in the second quarter of 2020. Research and development expenses included$2.7 million in severance payments and other employee-related costs associated with restructuring. - G&A Expenses: General and administrative expenses were
$72.3 million for the year ended December 31, 2021, an increase of$39.2 million , or 118 percent, compared to$33.2 million for the year ended December 31, 2020. The increase in general and administrative expenses was primarily due to an increase in costs associated with preparations for the commercial launch of tenapanor. General and administrative employee-related expenses included$3.5 million in severance payments and other employee-related costs associated with restructuring. - Net Loss: Net loss for the year ended December 31, 2021, was
$158.2 million , compared to$94.3 million for the year ended December 31, 2020.
Conference Call Details
The company will host a conference call today, February 28, 2022, at 4:30 PM ET to discuss today's announcement. To participate in the conference call, please call (855) 296-9612 (toll-free) or (920) 663-6277 (toll) and reference call ID number 2790368. A webcast of the call can also be accessed by visiting the Investor page of the company's website www.ardelyx.com and will be available on the website for 30 days following the call.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age. |
CONTRAINDICATIONS
- IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
- IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients
- IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
- Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.
Diarrhea
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥
INDICATION
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.
Please see full Prescribing Information, including Boxed Warning, for additional risk information.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx's expectation regarding the timing of a response from OND with respect to Ardelyx's submission of an appeal from the ADL issued by OCHEN; Ardelyx's expectations regarding the impact that the execution of a new loan and security agreement with SLR will have on Ardelyx's cash position; Ardelyx's expectations regarding the potential for breakeven and, ultimately, profitability for IBSRELA; Ardelyx's expectations regarding the impact on shareholder value that may result from the launch of IBSRELA; Ardelyx's expectations regarding the timing for filing for marketing approval for tenapanor for hyperphosphatemia in Japan by Ardelyx's collaboration partner, KKC and Ardelyx's expectations regarding the potential timing for KKC's marketing approval in Japan. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the Formal Dispute Resolution process with the FDA, uncertainties associated with its capital requirements to fund its operations, uncertainties in the commercialization of drugs in the United States, as well as uncertainties in the drug development and regulatory processes in Japan. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2022, and its future current and periodic reports to be filed with the Securities and Exchange Commission.
Ardelyx, Inc. | |||
Condensed Balance Sheets | |||
(In thousands) | |||
December 31, | |||
2021 | 2020 | ||
(Unaudited) | (1) | ||
Assets | |||
Cash and cash equivalents | $ 72,428 | $ 91,032 | |
Investments | 44,261 | 97,566 | |
Accounts receivable | 502 | — | |
Property and equipment, net | 2,362 | 1,936 | |
Right-of-use assets | 12,752 | 2,274 | |
Prepaid and other assets | 17,608 | 8,754 | |
Total assets | $ 149,913 | $ 201,562 | |
Liabilities and stockholders' equity | |||
Accounts payable | $ 4,277 | $ 5,626 | |
Accrued compensation and benefits | 5,422 | 5,672 | |
Current portion of operating lease liability | 3,492 | 2,117 | |
Loan payable, current portion | 32,264 | 4,167 | |
Deferred revenue | 4,727 | 4,177 | |
Accrued expenses and other liabilities | 7,366 | 6,657 | |
Operating lease liability, net of current portion | 9,748 | 413 | |
Loan payable, net of current portion | — | 46,621 | |
Stockholders' equity | 82,617 | 126,112 | |
Total liabilities and stockholders' equity | $ 149,913 | $ 201,562 | |
(1) Derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. |
Ardelyx, Inc. | |||||||
Condensed Statements of Operations | |||||||
(Unaudited) | |||||||
(In thousands, except share and per share amounts) | |||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||
2021 | 2020 | 2021 | 2020 | ||||
Revenues: | |||||||
Collaborative development revenue | $ 527 | $ 1,708 | $ 4,177 | $ 5,364 | |||
Product supply revenue | 496 | 101 | 907 | 1,501 | |||
Licensing revenue | 6 | — | 5,013 | 706 | |||
Total revenues | 1,029 | 1,809 | 10,097 | 7,571 | |||
Operating expenses: | |||||||
Cost of revenue | — | 4 | 1,000 | 145 | |||
Research and development | 20,968 | 18,105 | 91,140 | 65,053 | |||
General and administrative | 15,334 | 11,343 | 72,303 | 33,153 | |||
Total operating expenses | 36,302 | 29,452 | 164,443 | 98,351 | |||
Loss from operations | (35,273) | (27,643) | (154,346) | (90,780) | |||
Interest expense | (984) | (1,314) | (4,502) | (5,099) | |||
Other income, net | 23 | 83 | 687 | 1,568 | |||
Loss before provision for income taxes | (36,234) | (28,874) | $ (158,161) | $ (94,311) | |||
Provision for income taxes | — | 2 | 4 | 2 | |||
Net loss | $ (36,234) | $ (28,876) | $ (158,165) | $ (94,313) | |||
Net loss per common share, basic and diluted | $ (0.31) | $ (0.32) | $ (1.52) | $ (1.05) | |||
Shares used in computing net loss per share - basic and | 115,260,610 | 90,988,968 | 104,205,645 | 89,582,138 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-highlights-301491962.html
SOURCE Ardelyx
